Distribution of plasma folate forms in hemodialysis patients receiving high daily doses of L-folinic or folic acid

Kidney International

Volumn 62, Issue 6, 2002, Pages 2246-2249

  Ghandour, Haifa ^a,b   Bagley, Pamela J ^a,b   Shemin, Douglas ^a,b   Hsu, Natalie ^a,b   Jacques, Paul F ^a,b   Dworkin, Lance ^a,b   Bostom, Andrew G ^a,b   Selhub, Jacob ^a,b  

^a TUFTS UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

5 methyltetrahydrofolate; End stage renal disease; Homocysteine; Hyperhomocysteinemia; Maintenance hemodialysis; Pteroyglutamic acid

Indexed keywords

ANTIANEMIC AGENT; FOLIC ACID; 5 METHYLTETRAHYDROFOLIC ACID; CYANOCOBALAMIN; FOLIC ACID DERIVATIVE; FOLINIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HYPERHOMOCYSTEINEMIA; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; AFFINITY CHROMATOGRAPHY; BLOOD LEVEL; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FOLATE METABOLISM; FOLIC ACID BLOOD LEVEL; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL;

FOLIC ACID; HEMATINICS; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 0036433579     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00666.x     Document Type: Article

References (16)

1. Bostom AG, Culleton B: Hyperhomocysteinemia in chronic renal disease: Disease of the month review. J Am Soc Nephrol 10:891-900, 1999
2. Bostom AG, Shemin D, Lapane KL, et al: High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49:147-152, 1996
3. Touam M, Zingraff J, Jungers P, et al: Effective correction of hyperhomocysteinemia in hemodialysis patients by folinic acid and pyridoxine therapy. Kidney Int 56:2292-2296, 1999
4. Bostom AG, Shemin D, Bagley P, et al: Controlled comparison of 5-L-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation 101:2829-2832, 2000
5. Yango A, Shemin D, Hsu N, et al: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Kidney Int 59:324-327, 2001
6. Bagley PJ, Selhub J: Analysis of folate form distribution by affinity followed by reversed-phase chromatography with electrical detection. Clin Chem 46:404-411, 2000
7. Said HM, Vaziri ND, Kariger RK, et al: Intestinal absorption of 5-methyltetrahydrofolate in experimental uremia. Acta Vitaminol Enzymol 6:339-346, 1984
8. Retief FP, Heyns AP, Oosthuizen M, et al: Aspects of folate metabolism in renal failure. Br J Hematol 36:405-415, 1997
9. Jennrette JC, Goldman ID: Inhibition of the membrane transport of folates by anions retained in uremia. J Clin Lab Med 86:834-843, 1975
10. Livant EJ, Tamura T, Johnston KE, et al: Plasma folate conjugase activities and folate concentrations in patients receiving hemodialysis. J Nutr Biochem 5:504-508, 1994
11. Massy ZA: Reversal of hyperhomocysteinemia in chronic renal failure: Is folic or folinic acid the answer? Nephrol Dial Transplant 14:2810-2812, 1999
12. Selhub J, Miller JW: The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 55:131-138, 1992
13. Tremblay R, Bonnardeaux A, Geadah D, et al: Hyperhomocysteinemia in hemodialysis patients: Effects of 12-month supplementation with hydrosoluble vitamins. Kidney Int 58:851-858, 2000
14. Schmitz JC, Stuart RK, Priest DG: Disposition of folic acid and its metabolites: A comparison with leucovorin. Clin Pharmacol Ther 55:501-508, 1994
15. Bostom AG, Brosnan JT, Hall B, et al: Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerossis 116:59-62, 1995
16. Van Guldener C, Stehouwer CD: Homocysteine-lowering treatment: An overview. Expert Opin Pharmacother 2:1449-1460, 2001